| Name | Title | Contact Details |
|---|
Health Management Corporation of America is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the cancer continuum. With a leading portfolio of products for earlier detection and treatment guidance, we help people face the most challenging decisions with confidence. Our dedication to taking on the impossible fuels everything we do. We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing. We are Exact Sciences, and we`re changing lives together through earlier detection and smarter answers.
AMRO Environmental Laboratories Corporation is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More Health Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.